Teva's injunction on introduction of Mylan's generic Copaxone denied

PITTSBURGH — Mylan on Friday announced that Supreme Court Chief Justice John Roberts has denied Teva's application for an injunction seeking to prevent Mylan's launch of a generic version of Copaxone (glatiramer acetate injection) pending the Supreme Court's decision on Teva's appeal. This is the second time that the Chief Justice has denied Teva's request for such an injunction. 

In March, the Supreme Court granted Teva's petition for certiorari seeking clarification of the standard of review that appellate courts should apply when considering appeals relating to the construction of a patent claim. Oral argument is expected to be heard in the fall of 2014.  

"We look forward to introducing the first gene treatment for multiple sclerosis patients in the U.S. at market formation," stated Heather Bresch, Mylan CEO. "Mylan remains eligible to receive approval from the U.S. Food and Drug Administration on May 25, 2014."

 

 

 

Login or Register to post a comment.